ENTITY
Pharmaron Beijing

Pharmaron Beijing (300759 CH)

109
Analysis
Health Care • China
Pharmaron Beijing Co., Ltd. engages in discovery, development, and manufacturing spectrum for small molecule drugs, cell therapies, and gene therapies as well as providing testing services for medical devices and clinic research. The Company offers laboratory, clinical development, chemistry manufactory and control, and other services. Pharmaron Beijing conducts businesses based in China.
more
bullish•WuXi XDC
•08 Nov 2023 10:05

WuXi XDC IPO: Valuation Insights

Blue-chip cornerstones will purchase US$300 million of the offer. Our base-case DCF valuation is HK$22.84 per share, 12.8% above the midpoint of...

Logo
728 Views
Share
bullish•WuXi XDC
•06 Nov 2023 21:16

WuXi XDC IPO: Valuation First-Look

WuXi XDC is pre-marketing an HKEx IPO to raise US$500m. In this note, we present our forecasts and take the first look at the potential valuation...

Logo
733 Views
Share
•02 Nov 2023 09:48

Past A/H Listings Performance - Have Been a Mixed Bag

Two of the biggest deals in the Hong Kong pipeline are A/H listings for S.F. Holding (002352 CH) and Midea Group (000333 CH). In this note, we have...

Logo
542 Views
Share
bearish•WuXi XDC
•01 Nov 2023 18:21

WuXi XDC IPO: The Bear Case

The bear case rests on margins on a downward trend, large customer concentration, high related party transactions and volatile FCF generation.

Logo
678 Views
Share
•15 Oct 2023 10:10

A-H Premium Weekly (Oct 13th): Wuapptec, Tsingtao Brew, China Telecom, China Southern

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Wuapptec, Tsingtao Brew, China Telecom and China Southern.

Logo
573 Views
Share
x